Media Articles Related to Xifaxan (Rifaximin)
Drugs Identified With Fewest Side-Effects For Treating Irritable Bowel Syndrome
Source: Irritable-Bowel Syndrome News From Medical News Today [2012.03.28]
Cedars-Sinai researchers have determined that two prevalent drug therapies - rifaximin and lubiprostone - offer some of the best options for treating irritable bowel syndrome, a widespread disorder that affects up to one in five Americans...
IBS Drugs With Fewest Side Effects Identified
Source: Irritable-Bowel Syndrome News From Medical News Today [2012.03.27]
A new review of published research has identified drugs for treating irritable bowel syndrome (IBS) with the fewest side effects. The researchers find that two commonly used drugs, rifaximin and lubiprostone, offer the best options for treating the widespread disorder that affects one in five Americans...
Published Studies Related to Xifaxan (Rifaximin)
[Role of rifaximin in the treatment of colonic diverticular disease]. [Article in Italian] 
Diverticular disease of the colon is the fifth most important gastrointestinal
disease in terms of direct and indirect healthcare costs in western countries. Although most patients with colonic diverticula remain asymptomatic for their
whole life, in 20-25% of cases will develop symptoms.No definitive conclusion can be drawn regard a possible role
of rifaximin for preventing diverticulitis.
Double-blind randomized controlled trial of rifaximin for persistent symptoms in patients with celiac disease. [2011.10]
BACKGROUND: Small intestinal bacterial overgrowth (SIBO) is one cause of a poor response to a gluten-free diet (GFD) and persistent symptoms in celiac disease. Rifaximin has been reported to improve symptoms in non-controlled trials. AIMS: To determine the effect of rifaximin on gastrointestinal symptoms and lactulose-hydrogen breath tests in patients with poorly responsive celiac disease... CONCLUSIONS: Rifaximin does not improve patients' reporting of gastrointestinal symptoms and hydrogen breath tests do not reliably identify who will respond to antibiotic therapy.
Rifaximin: new therapeutic indication and future directions. [2011.07]
BACKGROUND: Rifaximin is a nonabsorbable oral antibiotic that acts locally in the gastrointestinal tract with minimal systemic adverse effects. Rifaximin received new labeling for reduction in the risk of the recurrence of overt hepatic encephalopathy (HE) in patients with advanced liver disease in March of 2010. OBJECTIVE: This article reviews the pharmacology, pharmacokinetics, and pharmacodynamics of rifaximin. The efficacy and safety of rifaximin in reducing the risk of the recurrence of overt HE in patients with advanced liver disease, the new US Food and Drug Administration-approved indication, is the focus of this review. Emerging data on the use of rifaximin in irritable bowel syndrome (IBS) and Clostridium difficile infection (CDI) are also evaluated... CONCLUSIONS: Rifaximin can be an effective option for reduction in the risk of the recurrence of HE in patients with advanced liver disease. Studies suggest that rifaximin provides relief of global symptoms of diarrhea-predominant IBS and bloating. Use of rifaximin in CDI requires further study. Copyright (c) 2011 Elsevier HS Journals, Inc. All rights reserved.
Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial. [2011.06]
The aim of this study was to evaluate the efficacy of levofloxacin and rifaximin based quadruple regimen as first-line treatment for Helicobacter pylori infection. A prospectively randomized, double-blinded, parallel group, comparative study was performed...
Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence. [2011.05]
Hepatic encephalopathy (HE) is a common problem in patients with chronic liver disease and is characterized by diminished mentation and neuromuscular abnormalities.It is recommended that patients with a history of recurrent acute HE should be maintained on rifaximin with or without lactulose to reduce the risk of recurrent HE and related hospitalization.
Clinical Trials Related to Xifaxan (Rifaximin)
Induction of Clinical Response Using Rifaximin in Crohn's Disease [Recruiting]
Antibiotics have been used to treat Crohn's disease symptoms with the best studied
antibiotics being Cipro and Flagyl. Rifaximin is a poorly absorbed oral antibiotic that is
FDA approved for travelers' diarrhea. It works by inhibiting bacterial reproduction. It is
very poorly absorbed and over 97% of the drug taken orally is excreted in the feces.
The purpose of this study is to evaluate the potential benefits and safety of Rifaximin for
the treatment of moderate to severe symptoms of Crohn's Disease.
Rifaximin Treatment of Papulopustular Rosacea [Not yet recruiting]
The purpose of this study is to determine the effects of rifaximin on skin symptoms in
patients with rosacea by double-blinded, placebo-controlled, crossover study.
Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease [Recruiting]
For HIV-infected patients who have access to treatment, liver diseases are a major cause of
morbidity and mortality. Hepatitis C is the most frequently encountered liver condition in
this population. Both diseases allow a higher level of poisonous substances (toxins)
normally produced by the bacteria present in the gut to enter the bloodstream. This leads to
a chronic inflammatory state, which results in faster development of liver scars (fibrosis)
and ultimately, end stage disease (cirrhosis). To prevent this from happening, the use of
antibiotics has been attempted to reduce the quantity of gut flora in the hopes of lowering
the amount of toxins produced. These trials have shown promising results, but the
antibiotics studied had major side effects and were not designed for continuous use.
Rifaximin is a non absorbable antibiotic with very few side effects. It is already used for
long periods of time in cirrhotic patients to treat the effects of cirrhosis on the brain
(encephalopathy). This project will try to determine if rifaximin, by reducing the level of
toxins produced by the bacteria in the gut, can improve the evolution of liver fibrosis in
HIV-infected patients with hepatitis C. In this pilot study, ten patients will be followed
for one year. They will be included if they are starting on rifaximin, for its currently
approved FDA indication (hepatic encephalopathy).
A Pilot Study of Xifaxan to Treat Patients With PSC [Recruiting]
In the current protocol, we propose the assessment of potential beneficial effects of the
antibiotic Xifaxan on liver biochemistries, liver related symptoms and Mayo risk score in 15
adult and 5 pediatric patients with PSC. Adult patients will receive Xifaxan, 550 mg twice
daily over a 12-week period. Pediatric patients with PSC whose weight is greater than or
equal to 40 kg will receive Xifaxan, 550 mg twice daily.
Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant [Recruiting]
The purpose of this study is to determine if the administration of a poorly-absorbable
antibiotic (rifaximin) for the first three months after liver transplant will reduce the
amount of fibrosis (or scarring of the liver) in liver transplant patients with recurrent
hepatitis C virus (HCV) by lowering serum lipopolysaccharide (LPS), a protein in blood that
comes from the bacteria in intestines and may cause scarring in the liver.
Approximately 60 subjects will participate in this study. Subjects will be part of the
study for approximately 1 year post transplant.
Reports of Suspected Xifaxan (Rifaximin) Side Effects
Renal Failure (5),
Colitis Ischaemic (3),
Staphylococcal Infection (3),
Enterococcal Infection (2),
Hepatic Failure (2),
Bacterial Prostatitis (2),
Oedema Peripheral (2), more >>